Circulating Mitochondrial DNA in Patients in the ICU as a Marker of Mortality: Derivation and Validation

English version České info

Background:
Mitochondrial DNA (mtDNA) is a critical activator of inflammation and the innate immune system. However, mtDNA level has not been tested for its role as a biomarker in the intensive care unit (ICU). We hypothesized that circulating cell-free mtDNA levels would be associated with mortality and improve risk prediction in ICU patients.

Methods and Findings:
Analyses of mtDNA levels were performed on blood samples obtained from two prospective observational cohort studies of ICU patients (the Brigham and Women's Hospital Registry of Critical Illness [BWH RoCI, n = 200] and Molecular Epidemiology of Acute Respiratory Distress Syndrome [ME ARDS, n = 243]). mtDNA levels in plasma were assessed by measuring the copy number of the NADH dehydrogenase 1 gene using quantitative real-time PCR. Medical ICU patients with an elevated mtDNA level (≥3,200 copies/µl plasma) had increased odds of dying within 28 d of ICU admission in both the BWH RoCI (odds ratio [OR] 7.5, 95% CI 3.6–15.8, p = 1×10⁻⁷) and ME ARDS (OR 8.4, 95% CI 2.9–24.2, p = 9×10⁻⁵) cohorts, while no evidence for association was noted in non-medical ICU patients. The addition of an elevated mtDNA level improved the net reclassification index (NRI) of 28-d mortality among medical ICU patients when added to clinical models in both the BWH RoCI (NRI 79%, standard error 14%, p<1×10⁻⁴) and ME ARDS (NRI 55%, standard error 20%, p = 0.007) cohorts. In the BWH RoCI cohort, those with an elevated mtDNA level had an increased risk of death, even in analyses limited to patients with sepsis or acute respiratory distress syndrome. Study limitations include the lack of data elucidating the concise pathological roles of mtDNA in the patients, and the limited numbers of measurements for some of biomarkers.

Conclusions:
Increased mtDNA levels are associated with ICU mortality, and inclusion of mtDNA level improves risk prediction in medical ICU patients. Our data suggest that mtDNA could serve as a viable plasma biomarker in medical ICU patients.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Circulating Mitochondrial DNA in Patients in the ICU as a Marker of Mortality: Derivation and Validation. PLoS Med 10(12): e32767. doi:10.1371/journal.pmed.1001577
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001577

Souhrn

Zdroje

1. PierrakosC, VincentJL (2010) Sepsis biomarkers: a review. Crit Care 14: R15.

2. SchetzMR, Van den BergheG (2005) Do we have reliable biochemical markers to predict the outcome of critical illness? Int J Artif Organs 28: 1197–1210.

3. AduenJ, BernsteinWK, KhastgirT, MillerJ, KerznerR, et al. (1994) The use and clinical importance of a substrate-specific electrode for rapid determination of blood lactate concentrations. JAMA 272: 1678–1685.

4. Christ-CrainM, Jaccard-StolzD, BingisserR, GencayMM, HuberPR, et al. (2004) Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 363: 600–607.

5. PyleA, BurnDJ, GordonC, SwanC, ChinneryPF, et al. (2010) Fall in circulating mononuclear cell mitochondrial DNA content in human sepsis. Intensive Care Med 36: 956–962.

6. SulimanHB, Welty-WolfKE, CarrawayMS, SchwartzDA, HollingsworthJW, et al. (2005) Toll-like receptor 4 mediates mitochondrial DNA damage and biogenic responses after heat-inactivated E. coli. FASEB J 19: 1531–1533.

7. ZhangQ, RaoofM, ChenY, SumiY, SursalT, et al. (2010) Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 464: 104–107.

8. LuCH, ChangWN, TsaiNW, ChuangYC, HuangCR, et al. (2010) The value of serial plasma nuclear and mitochondrial DNA levels in adult community-acquired bacterial meningitis. QJM 103: 169–175.

9. CossarizzaA, PintiM, NasiM, GibelliniL, ManziniS, et al. (2011) Increased plasma levels of extracellular mitochondrial DNA during HIV infection: a new role for mitochondrial damage-associated molecular patterns during inflammation. Mitochondrion 11: 750–755.

10. SursalT, Stearns-KurosawaDJ, ItagakiK, OhSY, SunS, et al. (2013) Plasma bacterial and mitochondrial DNA distinguish bacterial sepsis from sterile systemic inflammatory response syndrome and quantify inflammatory tissue injury in nonhuman primates. Shock 39: 55–62.

11. KryskoDV, AgostinisP, KryskoO, GargAD, BachertC, et al. (2011) Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol 32: 157–164.

12. NakahiraK, HaspelJA, RathinamVA, LeeSJ, DolinayT, et al. (2011) Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol 12: 222–230.

13. CollinsLV, HajizadehS, HolmeE, JonssonIM, TarkowskiA (2004) Endogenously oxidized mitochondrial DNA induces in vivo and in vitro inflammatory responses. J Leukoc Biol 75: 995–1000.

14. DolinayT, KimYS, HowrylakJ, HunninghakeGM, AnCH, et al. (2012) Inflammasome-regulated cytokines are critical mediators of acute lung injury. Am J Respir Crit Care Med 185: 1225–1234.

15. GongMN, SaiY, ZhouW, ThompsonBT, XuLL, et al. (2003) Genotyping patients with recent blood transfusions. Epidemiology 14: 744–747.

16. SheuCC, GongMN, ZhaiR, ChenF, BajwaEK, et al. (2010) Clinical characteristics and outcomes of sepsis-related vs non-sepsis-related ARDS. Chest 138: 559–567.

17. ClermontG, AckerCG, AngusDC, SirioCA, PinskyMR, et al. (2002) Renal failure in the ICU: comparison of the impact of acute renal failure and end-stage renal disease on ICU outcomes. Kidney Int 62: 986–996.

18. LevyMM, FinkMP, MarshallJC, AbrahamE, AngusD, et al. (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31: 1250–1256.

19. BernardGR, ArtigasA, BrighamKL, CarletJ, FalkeK, et al. (1994) The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 149: 818–824.

20. KnausWA, DraperEA, WagnerDP, ZimmermanJE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13: 818–829.

21. AbrahamE, LaterrePF, GargR, LevyH, TalwarD, et al. (2005) Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353: 1332–1341.

22. HillME, RosenwaikeI (2001) The Social Security Administration's Death Master File: the completeness of death reporting at older ages. Soc Secur Bull 64: 45–51.

23. BajwaEK, KhanUA, JanuzziJL, GongMN, ThompsonBT, et al. (2009) Plasma C-reactive protein levels are associated with improved outcome in ARDS. Chest 136: 471–480.

24. McGillMR, SharpeMR, WilliamsCD, TahaM, CurrySC, et al. (2012) The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation. J Clin Invest 122: 1574–1583.

25. MoreiraVG, PrietoB, RodriguezJS, AlvarezFV (2010) Usefulness of cell-free plasma DNA, procalcitonin and C-reactive protein as markers of infection in febrile patients. Ann Clin Biochem 47: 253–258.

26. NgaTV, KarkeyA, DongolS, ThuyHN, DunstanS, et al. (2010) The sensitivity of real-time PCR amplification targeting invasive Salmonella serovars in biological specimens. BMC Infect Dis 10: 125.

27. Zozaya-HinchliffeM, MartinDH, FerrisMJ (2008) Prevalence and abundance of uncultivated Megasphaera-like bacteria in the human vaginal environment. Appl Environ Microbiol 74: 1656–1659.

28. ChiuRW, ChanLY, LamNY, TsuiNB, NgEK, et al. (2003) Quantitative analysis of circulating mitochondrial DNA in plasma. Clin Chem 49: 719–726.

29. HosmerDW, TaberS, LemeshowS (1991) The importance of assessing the fit of logistic regression models: a case study. Am J Public Health 81: 1630–1635.

30. CookNR (2007) Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 115: 928–935.

31. May Clinic Division of Biomedical Statistics and Informatics (2013) Locally written SAS macros. Available: http://www.mayo.edu/research/departments-divisions/department-health-sciences-research/division-biomedical-statistics-informatics/software/locally-written-sas-macros. Accessed 23 August13.

32. van der VaartM, PretoriusPJ (2008) Circulating DNA. Its origin and fluctuation. Ann N Y Acad Sci 1137: 18–26.

33. DavisBK, WenH, TingJP (2011) The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 29: 707–735.

34. Henao-MejiaJ, ElinavE, StrowigT, FlavellRA (2012) Inflammasomes: far beyond inflammation. Nat Immunol 13: 321–324.

35. MakabeH, KojikaM, TakahashiG, MatsumotoN, ShibataS, et al. (2012) Interleukin-18 levels reflect the long-term prognosis of acute lung injury and acute respiratory distress syndrome. J Anesth 26: 658–663.

36. EscamesG, LopezLC, GarciaJA, Garcia-CorzoL, OrtizF, et al. (2012) Mitochondrial DNA and inflammatory diseases. Hum Genet 131: 161–173.

37. KungCT, HsiaoSY, TsaiTC, SuCM, ChangWN, et al. (2012) Plasma nuclear and mitochondrial DNA levels as predictors of outcome in severe sepsis patients in the emergency room. J Transl Med 10: 130.

38. BaudouinSV, SaundersD, TiangyouW, ElsonJL, PoynterJ, et al. (2005) Mitochondrial DNA and survival after sepsis: a prospective study. Lancet 366: 2118–2121.

39. KraftP, WacholderS, CornelisMC, HuFB, HayesRB, et al. (2009) Beyond odds ratios—communicating disease risk based on genetic profiles. Nat Rev Genet 10: 264–269.

40. KathiresanS, MelanderO, AnevskiD, GuiducciC, BurttNP, et al. (2008) Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 358: 1240–1249.

41. Rangel-FraustoMS, PittetD, CostiganM, HwangT, DavisCS, et al. (1995) The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 273: 117–123.

42. PittetD, Rangel-FraustoS, LiN, TararaD, CostiganM, et al. (1995) Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: incidence, morbidities and outcomes in surgical ICU patients. Intensive Care Med 21: 302–309.

43. DowlerWM, ShawPD, GottliebD (1963) Terminal oxidation in cell-free extracts of fungii. J Bacteriol 86: 9–17.